logo
  

Deciphera Pharma Reports Approval Of QINLOCK In Switzerland - Quick Facts

Deciphera Pharmaceuticals, Inc. (DCPH) announced the Swiss Agency for Therapeutic Products or Swissmedic, has granted approval for QINLOCK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib.

"The approval in Switzerland is our seventh approval worldwide and the first in Europe," said Steve Hoerter, CEO of Deciphera.

The company anticipates a potential approval from the European Commission for QINLOCK in the fourth quarter of the current year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Goldman Sachs Group, Inc. (GS) reported that its third quarter net earnings applicable to common shareholders increased 63 percent year-on-year. Net revenues were also significantly higher reflecting significantly higher net revenues in Investment Banking, Global Markets and Consumer & Wealth Management,... Butterball, LLC recalled about 14,107 pounds of ground turkey products for potential contamination with foreign materials, specifically blue plastic material, the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) said in a statement. Specialized Bicycle Components, Inc. is recalling about 6,900 units of Tarmac SL7 Bicycles and Framesets for potential risk of fall and injury hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the bicycle's fork steerer tube can crack or break after harsh impact such as hitting a deep pothole or other stress event, posing fall and injury hazards.
Follow RTT